✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Most peptides in the longevity and recovery space work on muscle, tendon, or mitochondria. PT-141 — formally known as bremelanotide — is one of the only ones that works on the brain, and specifically on the circuits that govern sexual desire. It is also one of the very few peptides in this guide series to have crossed the finish line into full FDA approval as a prescription drug.

In 2019, the FDA approved bremelanotide under the trade name Vyleesi for acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval followed two identical Phase 3 trials and more than a decade of earlier development by Palatin Technologies. The approval matters: it means the pharmacokinetics, safety profile, and dosing for PT-141 have been scrutinised at a level very few research peptides ever reach.

This guide is the deep dive on what PT-141 actually is, how it works in the brain, what the clinical evidence shows for both women and men, what realistic dosing protocols look like, and the genuine risks — blood-pressure rises, nausea, and hyperpigmentation — that the “peptide cures everything” content never mentions.

PT-141 (Bremelanotide) Peptide: Benefits, Dosage & The Honest Science (2026)

Last updated: April 17, 2026 · Reviewed by a licensed pharmacist (MedsBase Medical Team)

What Is PT-141? (Definition & Background)

PT-141 — chemical name bremelanotide — is a synthetic cyclic heptapeptide (seven amino acids arranged in a closed ring). It was originally developed from melanotan II, a broader melanocortin agonist that researchers noticed was producing unexpected sexual-arousal effects during studies aimed at skin pigmentation and tanning. The pharmaceutical team at Palatin Technologies isolated and refined that arousal-related activity into a cleaner molecule, PT-141, in the early 2000s.

The original clinical ambition was broad: PT-141 was investigated first as an intranasal spray for erectile dysfunction in men. Early Phase 2 data was promising, but the nasal formulation ran into dose-dependent blood-pressure increases that pushed the FDA toward a narrower indication. Palatin pivoted to subcutaneous injection and to HSDD in premenopausal women — a condition where no FDA-approved drug existed at that point. Vyleesi was approved in June 2019 after two Phase 3 trials (RECONNECT), making PT-141 one of only two FDA-approved drugs for female sexual dysfunction (the other being flibanserin).

The molecule itself is small by peptide standards — just seven amino acids, cyclically constrained for stability. That small size gives it two useful properties: predictable subcutaneous absorption, and the ability to cross the blood–brain barrier in meaningful amounts. Unlike most peptides discussed in longevity and recovery medicine, PT-141 does its work centrally, not peripherally. It is a brain drug, not a muscle drug.

How Does PT-141 Work? (Mechanism & Science)

PT-141 is a non-selective agonist at several melanocortin receptors — MC1R, MC3R, MC4R, and MC5R — with the sexual-desire effect driven primarily by MC4R activation in specific hypothalamic and limbic regions.

1. The MC4R–Dopamine Axis

The melanocortin-4 receptor is expressed densely in the paraventricular nucleus (PVN) of the hypothalamus and in downstream regions that regulate reward, motivation, and autonomic tone. When bremelanotide binds MC4R, it triggers a cascade that increases dopamine release in the medial preoptic area — a brain region that has been mapped in both animals and humans to the “desire” rather than “mechanics” side of sexual function.

This is the fundamental reason PT-141 is unlike sildenafil and tadalafil. PDE5 inhibitors amplify the vascular response after arousal is already present. PT-141 acts upstream of the vascular response — it increases the arousal itself. In patients for whom the bottleneck is psychological rather than vascular, this distinction matters enormously.

2. The MC1R “Side Channel” and Pigmentation

MC1R controls skin pigmentation, and PT-141’s non-selective activity at this receptor explains one of the most talked-about side effects: transient skin darkening or new freckles in rare cases with heavy or frequent use. The 8-dose-per-month limit on the FDA label exists partly to prevent this. Daily dosing — which some unsupervised users attempt — produces focal hyperpigmentation in roughly one in three users after 16 consecutive days.

3. The Cardiovascular Footprint

PT-141 causes transient blood-pressure rises, typically 2–6 mmHg systolic for 8–12 hours after each dose. For healthy users this is clinically insignificant. For anyone with uncontrolled hypertension, known cardiovascular disease, or ongoing stress on the cardiovascular system, the effect is meaningful enough that the FDA label contraindicates use. This is the single most important safety question to answer before starting PT-141.

Key Uses & Applications

Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women — On-Label

This is the FDA-approved indication and the use-case with the most rigorous evidence. HSDD is defined as persistent or recurrent deficiency of sexual thoughts, desire, or receptivity that causes personal distress and is not better explained by a medication, medical condition, or relationship issue. For this group, the Phase 3 data shows bremelanotide meaningfully improves desire, arousal, and satisfaction compared to placebo over 24 weeks of on-demand use.

Erectile Dysfunction & Low Libido in Men — Off-Label

This is where most underground use happens. The early intranasal PT-141 trials in men with ED produced meaningful response rates — one study reported 34 percent of bremelanotide users achieved erection sufficient for intercourse versus 9 percent for placebo. More interesting are the combination studies: co-administered with 25 mg sildenafil, the erectile response is consistently stronger than either drug alone. This is the clinical basis for the so-called “Viagra reboot” protocol that some andrology clinics use in PDE5-resistant patients. Off-label use in men is not FDA-approved and requires physician supervision — particularly for cardiovascular screening.

Postmenopausal Women — Off-Label, Limited Data

Although Vyleesi is approved only for premenopausal women, clinical practice has extended use to postmenopausal patients with similar symptoms. Small case series and physician reports are generally favourable, but formal trials in this population are limited. Caution around blood-pressure effects increases with age and is especially important for this group.

Neurogenic Sexual Dysfunction

A smaller, quieter line of research uses PT-141 in patients with sexual dysfunction secondary to spinal-cord injury, multiple sclerosis, or certain psychiatric medications (SSRIs in particular). The mechanism — central melanocortin activation — is theoretically well-suited to these conditions, but published data remains preliminary.

Safety Profile, Side Effects & Dosage

Common Side Effects

• Nausea — the dominant side effect, affecting roughly 40 percent of users. Usually peaks within 30–60 minutes, resolves within a few hours, and diminishes with subsequent doses in most people. Some clinicians recommend ondansetron 4–8 mg before the first few doses to blunt this.
• Flushing — warmth and facial flushing during the first hour, reported in 20–25 percent of users. Short-lived and benign.
• Headache — reported in 10–15 percent, typically mild.
• Injection-site reactions — small bumps, redness, or brief itching at the subcutaneous injection site, usually resolving within hours.
• Transient blood-pressure increase — 2–6 mmHg systolic, peaking 2–4 hours post-dose, fully resolved by 12 hours in healthy users.

Uncommon and Rare Effects

• Focal hyperpigmentation — localised darkening of skin patches (especially on face, gums, or breasts), tied to MC1R activity. Rare at label dosing, more common with daily use or with doses above the recommended 1.75 mg.
• Fatigue and “hangover” feeling — the day after a dose, mentioned in a minority of users.
• Vivid dreams — reported occasionally, thought to reflect central melanocortin activity.

Dosage Reference Ranges

These are observational clinical ranges, not personal recommendations.

• Vyleesi label (women, HSDD): 1.75 mg SC, 45 minutes before anticipated sexual activity. Maximum 1 dose per 24 hours and 8 doses per month.
• Off-label male use: 1.0–2.0 mg SC, 30–60 minutes before sexual activity, same maximum monthly limit.
• Starter dose: clinicians often begin at 0.5–1.0 mg to gauge tolerability before titrating up.
• Co-administration with sildenafil: PT-141 1.0 mg SC + sildenafil 25 mg orally has been used in ED protocols, but this stack raises cardiovascular risk and requires a cleared physician.

Absolute Contraindications

Uncontrolled hypertension, known cardiovascular disease (recent MI, stroke, unstable angina, severe heart failure), pregnancy, breastfeeding, active cancer with unclear melanocortin interaction, and use of MAOI antidepressants. Caution in severe kidney or liver impairment. Anyone with a history of melanoma should particularly avoid use because of MC1R activity.

What Does the Research Say?

RECONNECT (Phase 3, HSDD in Premenopausal Women)

Two identical 24-week randomised, double-blind, placebo-controlled trials (RECONNECT-1 and RECONNECT-2) enrolled more than 1,200 women combined. Both trials met co-primary endpoints: increase in the FSFI-desire score and decrease in the FSDS-DAO distress score for low desire. Effect sizes were modest in absolute terms but statistically significant and consistent across subgroups. Safety matched the long Phase 2 experience: nausea, flushing, headache, and small transient BP rises dominated. This was the dataset that supported FDA approval in 2019.

Intranasal PT-141 in Men with Erectile Dysfunction

Earlier Phase 2 work with intranasal bremelanotide in men showed a dose-dependent improvement in erection quality. The 34 percent response rate on bremelanotide versus 9 percent on placebo for achieving intercourse-grade erection was the headline number. Development of the intranasal formulation was paused over the blood-pressure signal, but the male efficacy data is what keeps off-label interest in subcutaneous dosing alive.

Combination Studies (PT-141 + Sildenafil)

A clinical study of co-administered subcutaneous PT-141 (7.5 mg) and oral sildenafil (25 mg) produced a significantly stronger erectile response than sildenafil alone in men with mild-to-moderate ED. This pharmacology — central arousal plus peripheral vascular amplification — is the theoretical sweet spot for the subset of men in whom neither mechanism alone is sufficient. Clinical use is restricted to carefully selected patients with cardiovascular clearance.

SSRI-Induced Sexual Dysfunction

Smaller trials have explored PT-141 in patients whose sexual side effects are medication-related, particularly from serotonergic antidepressants. Signal is positive but data is limited. This is a high-unmet-need population and an area to watch as more trials are published.

PT-141 vs Sildenafil, Tadalafil & Other Options

Understanding where PT-141 fits relative to other sexual-function treatments is essential. The drugs work on completely different pathways.

Practical takeaway. If the bottleneck is mechanical — difficulty maintaining erection despite normal desire — a PDE5 inhibitor is the first-line, well-studied, inexpensive answer. If the bottleneck is desire or arousal — particularly in women with HSDD, or in men whose PDE5 response is poor — PT-141 offers a fundamentally different mechanism worth investigating under supervision. The combination is reserved for selected cases that have failed either drug alone.

How to Use PT-141 (Reconstitution, Storage, Injection Technique)

Research-grade PT-141 typically ships as a lyophilised powder in 10 mg vials. It must be reconstituted with bacteriostatic water for injection before use. Sterile saline is acceptable but shortens post-reconstitution shelf life.

Reconstitution

Adding 2 mL of bacteriostatic water to a 10 mg vial produces a 5 mg/mL concentration. With that dilution, a 1.75 mg dose is 0.35 mL — 35 units on an insulin syringe marked in 100 units/mL. Inject the water slowly down the inside wall of the vial to avoid foaming; swirl gently until dissolved. The solution should be clear and colourless to very pale yellow.

Storage

Reconstituted PT-141 is stable refrigerated (2–8 °C) for 30+ days when made with bacteriostatic water. Unreconstituted vials keep for many months refrigerated or indefinitely frozen. Protect from light and avoid freeze–thaw cycles on reconstituted solution.

Subcutaneous Injection Technique

• Draw the dose into a 0.3–1 mL insulin syringe (29–31 gauge, 8–13 mm needle).
• Choose an injection site with loose subcutaneous tissue: abdomen (2 inches from navel), upper outer thigh, or back of upper arm.
• Clean with alcohol swab; let dry.
• Pinch skin, insert needle at 45–90°, aspirate briefly, push plunger over 5–10 seconds.
• Rotate sites between injections.

Timing matters. PT-141 works on central desire circuits — it is not a bedtime compound or a daily maintenance drug. Inject 30–60 minutes before anticipated sexual activity. If intimacy does not happen within a few hours of dosing, the dose is wasted but the side-effect window is not — nausea and blood-pressure rises still occur.

Frequently Asked Questions

What is PT-141 used for?

PT-141 is FDA-approved as Vyleesi for premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD). Off-label, it is used in men for erectile dysfunction (particularly PDE5-resistant cases), in women with HSDD outside the approved pre-menopausal population, and in patients with sexual side effects from SSRIs or neurological conditions. It is always an on-demand rather than daily drug.

Is PT-141 a peptide?

Yes. PT-141 (bremelanotide) is a cyclic heptapeptide — seven amino acids joined in a closed ring. It was derived from melanotan II, and its amino acid backbone is the core of its receptor-binding activity.

How quickly does PT-141 work?

Subcutaneous onset is 30–60 minutes to peak central effect, with most users reporting increased desire and arousal within 45 minutes. Effects last 4–6 hours. This is an on-demand drug — take it before, not after, the activity window.

Is PT-141 safer than Viagra or Cialis?

They have different safety profiles, not one clearly “safer.” PDE5 inhibitors are oral, very well-studied for three decades, and cheaper, but they cause headaches, flushing, visual changes, and are contraindicated with nitrates. PT-141 avoids most of those issues but adds significant nausea, transient blood-pressure rise, and a small hyperpigmentation risk. Cardiovascular screening is required for either drug but is especially important for PT-141 because the BP effect is consistent and clinically measurable.

How much PT-141 should I use?

The FDA-labeled dose is 1.75 mg SC 45 minutes before anticipated activity, max 1 per 24 hours and 8 per month. Clinicians often start at 0.5–1.0 mg to gauge tolerability (nausea especially) and titrate up. These figures are clinical observations; actual dosing should be set by a physician who understands your cardiovascular and medication history.

Can PT-141 help with SSRI-induced sexual dysfunction?

Small clinical studies and physician reports suggest yes, though formal trial data remains limited. The mechanism — central melanocortin activation bypassing the serotonergic blockade — fits the pharmacology well. This is one of the most promising off-label niches for PT-141. As always, discuss with the prescriber of the SSRI before adding a second centrally-acting agent.

Does PT-141 shut down natural libido?

No. PT-141 activates pre-existing melanocortin pathways on-demand; it does not suppress endogenous neurotransmitter systems or provoke downregulation when used at label frequency. Hyperpigmentation risk — not libido shutdown — is the dose-limiting factor with heavy use.

Can I stack PT-141 with other peptides?

Yes, carefully. PT-141 has no direct pharmacological overlap with recovery peptides like BPC-157 or growth-hormone-releasing peptides like ipamorelin and CJC-1295, so stacks for people running broader protocols are common. The only combinations that raise concern are with drugs affecting cardiovascular tone — sildenafil, tadalafil, or nitrates — which require medical supervision.

Is PT-141 legal?

In the United States, bremelanotide is a prescription drug (Vyleesi) approved for premenopausal women with HSDD. Off-label physician-supervised use is legal. Research-grade vials are sold for laboratory research use only and are not FDA-approved for therapeutic purposes outside the Vyleesi prescribing indication. Legal status varies in other jurisdictions; always check local laws. PT-141 is not specifically listed on the WADA banned list, but competitive athletes should check the current code before use.

The Bottom Line — Is PT-141 Worth It?

PT-141 is arguably the most medically validated peptide in the consumer sexual-health space. Its FDA approval as Vyleesi gives it a regulatory pedigree that no underground libido peptide can match, and its mechanism — central MC4R activation — addresses the one bottleneck that PDE5 inhibitors cannot touch. For premenopausal women with HSDD, PT-141 is one of only two approved pharmacological options and is a genuine clinical tool. For men with PDE5-resistant ED, it is a well-studied investigational option that deserves consideration under supervision. For patients with SSRI-induced or neurogenic dysfunction, it offers a mechanism-specific approach that nothing else on the market provides.

The trade-off is the side-effect profile. Nausea affects around 40 percent of users, transient blood-pressure rises rule out a meaningful subset of candidates, and the 8-dose-per-month ceiling limits PT-141 to occasional use rather than daily support. These are manageable issues for the right patient, not deal-breakers for the right use case — but they require honest pre-use screening.

For adults with the right indication, a cleared cardiovascular history, and realistic expectations, PT-141 earns its place in the modern sexual-health toolkit. It pairs well with other targeted interventions when used under supervision, and when a typical first-line drug has been tried and failed. To understand how it fits alongside other central peptides, see our sermorelin peptide guide or the mitochondrial NAD⁺ coenzyme guide for broader longevity context; for the peripheral-vascular side of the equation, PDE5 inhibitors remain the first-line oral option.

When you are ready to source high-purity research material, verified PT-141 at MedsBase ships with full documentation and pharmaceutical-grade purity in 10 mg vials. Used under proper medical supervision, it remains one of the most mechanistically defensible compounds in the entire consumer sexual-health toolkit.

Related Guides

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.